Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Ardelyx, Inc. - Common Stock (NQ: ARDX )

5.370 -0.100 (-1.83%)
Streaming Delayed Price Updated: 10:44 AM EDT, Mar 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 514,915
Open 5.430
Bid (Size) 5.360 (6)
Ask (Size) 5.370 (4)
Prev. Close 5.470
Today's Range 5.320 - 5.440
52wk Range 4.320 - 9.330
Shares Outstanding 103,119,010
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Ardelyx Announces the First Recipients of Derek Forfang Patient Advocate Award
Award established to recognize leaders in the field of chronic kidney disease advocacy 
From Ardelyx, Inc.
Via GlobeNewswire
Tenapanor Approved in China for Hyperphosphatemia
Ardelyx to receive $5 million milestone payment from Fosun Pharma following approval 
From Ardelyx, Inc.
Via GlobeNewswire

Performance

YTD
+4.88%
+4.88%
1 Month
-7.25%
-7.25%
3 Month
-0.37%
-0.37%
6 Month
-13.67%
-13.67%
1 Year
-31.51%
-31.51%

More News

Read More
Ardelyx to Participate in Upcoming Investor Conferences
From Ardelyx, Inc.
Via GlobeNewswire
Breaking Down Ardelyx: 4 Analysts Share Their Views
Via Benzinga
Earnings Scheduled For February 20, 2025
Via Benzinga
What Analysts Are Saying About Ardelyx Stock
Via Benzinga
Beyond The Numbers: 4 Analysts Discuss Ardelyx Stock
Via Benzinga
Ardelyx Stock Rises After-Hours On Q4 Beat, Drug Sales Outlook: Retail Gets Big Dose Of Optimism
Via Stocktwits
Ardelyx Tops Estimates as Sales Surge
Via The Motley Fool
Palantir Rally Loses Steam, Walmart Outlook Disappoints: What's Driving Markets Thursday?
Via Benzinga
Ardelyx Beats Q3 Sales Estimates, Shares Climb
Via Benzinga
Ardelyx's Earnings Outlook
Via Benzinga
Ardelyx Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
From Ardelyx, Inc.
Via GlobeNewswire
Ardelyx to Present at the TD Cowen 45th Annual Health Care Conference
From Ardelyx, Inc.
Via GlobeNewswire
Ardelyx to Report Full Year and Fourth Quarter 2024 Financial Results on February 20, 2025
From Ardelyx, Inc.
Via GlobeNewswire
Ardelyx Provides Update on Increasing Commercial Momentum and 2025 Strategic Priorities
From Ardelyx, Inc.
Via GlobeNewswire
Ardelyx to Present at the 43rd Annual J.P. Morgan Healthcare Conference
From Ardelyx, Inc.
Via GlobeNewswire
Ardelyx to Participate at the Piper Sandler 36th Annual Healthcare Conference
From Ardelyx, Inc.
Via GlobeNewswire
Ardelyx Responds to District Court Decision Granting Motion to Dismiss
From Ardelyx, Inc.
Via GlobeNewswire
Ardelyx to Participate at the 2024 Jefferies London Healthcare Conference
From Ardelyx, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
Ardelyx Reports Third Quarter 2024 Financial Results and Provides Business Update
From Ardelyx, Inc.
Via GlobeNewswire
Ardelyx Presents Results from its IBS in America 2024 Supplemental Survey at the American College of Gastroenterology’s (ACG) Annual Meeting
From Ardelyx, Inc.
Via GlobeNewswire
Ardelyx Shares Additional Data Supporting First-In-Class XPHOZAH® (tenapanor) at the American Society of Nephrology’s Kidney Week
From Ardelyx, Inc.
Via GlobeNewswire
ARDELYX ALERT: Bragar Eagel & Squire, P.C. is Investigating Ardelyx, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.